We are live on ! Find out more
CTNM

Contineum Therapeutics
CTNM

80 hedge funds and large institutions have $338M invested in Contineum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 29 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 8

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

64% more capital invested

Capital invested by funds: $206M → $338M (+$133M)

47.2% more ownership

Funds ownership: 80.95% → 128.15% (+47%)

29% more funds holding

Funds holding: 62 → 80 (+18)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

27% less call options, than puts

Call options by funds: $117K | Put options by funds: $160K

Holders
80
Holders Change
+18
Holders Change %
+29.03%
% of All Funds
0.97%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
29
Reduced
8
Closed
11
Calls
$117K
Puts
$160K
Net Calls
-$43K
Net Calls Change
-$273K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$27.9M
2
BBA
Baker Bros. Advisors
New York
+$15.3M
3
SCM
Suvretta Capital Management
New York
+$12.8M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$10.2M
5
CC
Commodore Capital
New York
+$9.31M

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$5.69M
2
BEAM
Baker Ellis Asset Management
Washington
-$229K
3
RC
RBF Capital
California
-$228K
4
Squarepoint
Squarepoint
New York
-$154K
5
B
Bailard
California
-$145K
Name Holding Trade Value Shares
Change 		Change in
Stake
BT
76
Banque Transatlantique
France
$2.51K +$2.51K +220 New
TRCT
77
Tower Research Capital (TRC)
New York
$1.42K -$17.7K -1,551 -93%
Optiver Holding
78
Optiver Holding
Netherlands
$1.19K – – –
Group One Trading
79
Group One Trading
Illinois
$1.18K -$4.53K -397 -79%
CFM
80
Cornerstone Financial Management
Massachusetts
$732 +$730 +64 New
BEAM
81
Baker Ellis Asset Management
Washington
– -$229K -19,500 Closed
Squarepoint
82
Squarepoint
New York
– -$154K -13,086 Closed
B
83
Bailard
California
– -$145K -12,350 Closed
Mariner
84
Mariner
Kansas
– -$122K -10,420 Closed
Wells Fargo
85
Wells Fargo
California
– -$63K -5,359 Closed
Simplex Trading
86
Simplex Trading
Illinois
– -$10K -895 Closed
EWA
87
EverSource Wealth Advisors
Alabama
– -$564 -48 Closed
TWD
88
True Wealth Design
Ohio
– -$447 -38 Closed
AAP
89
Arax Advisory Partners
Colorado
– -$94 -8 Closed
IA
90
IFP Advisors
Florida
– -$12 -1 Closed
SS
91
SBI Securities
Japan
– -$12 -1 Closed
1 2 3
4

CTNM Hedge Fund Activity: Q4 2025 in Review

80 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q4 2025, worth a combined $338M — up 64% from $206M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new CTNM positions and 11 closed out — a net gain of 20 holders — while 29 added to existing stakes and 8 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $27.9M. The largest seller was Samsara BioCapital, cutting an estimated $5.69M.

  • 80 institutional investors held Contineum Therapeutics (CTNM) as of Q4 2025, up from 62 in Q3 2025.
  • Funds reported $338M of Contineum Therapeutics stock for Q4 2025, up 64% quarter-over-quarter.
  • 31 funds opened new Contineum Therapeutics positions in Q4 2025 and 11 closed out, a net change of +20 holders.
  • The largest Contineum Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $27.9M added.
  • The largest Contineum Therapeutics seller in Q4 2025 was Samsara BioCapital, an estimated $5.69M sold.

Based on aggregated 13F filings for Q4 2025.